Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Leukemia, Myeloid, Acute 245Precursor Cell Lymphoblastic Leukemia-Lymphoma 143Myelodysplastic Syndromes 142Leukemia, Lymphocytic, Chronic, B-Cell 139Leukemia 127Multiple Myeloma 117Lymphoma 115Lymphoma, Non-Hodgkin 112Recurrence 79Hematologic Neoplasms 74Melanoma 68Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Hodgkin Disease 67Lymphoma, B-Cell 61Lymphoma, Mantle-Cell 51Lymphoma, Large B-Cell, Diffuse 50Lymphoma, Follicular 50Burkitt Lymphoma 41Ovarian Neoplasms 40Neoplasms 39Myeloproliferative Disorders 39Neoplasm Metastasis 34Lymphoma, B-Cell, Marginal Zone 30Graft vs Host Disease 29Neoplasms, Plasma Cell 28Carcinoma, Non-Small-Cell Lung 27Breast Neoplasms 27Leukemia, Biphenotypic, Acute 25Primary Myelofibrosis 24Anemia, Refractory, with Excess of Blasts 23

Interventions

pembrolizumab 7Nivolumab 5durvalumab 3fludarabine 2avelumab 2atezolizumab 2Cyclophosphamide 2tremelimumab 1relatlimab 1fludarabine phosphate 1epacadostat 1bintrafusp alfa protein, human 1aldesleukin 1Therapeutics 1Temozolomide 1Surgical Procedures, Operative 1Oxaliplatin 1Neoadjuvant Therapy 1Ipilimumab 1Interleukin-2 1Injections 1Immunoglobulin G 1Educational Status 1Docetaxel 1Disulfides 1Chemotherapy, Adjuvant 1Capecitabine 1Bevacizumab 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Microsatellite Instability × fludarabine × Clear all
NCT03935893 2026-06-01

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

University of Pittsburgh

Phase 2 Active not recruiting
20 enrolled
DermatologicEndocrineGastrointestinalNETOther solid neoplasmSarcomaThoracic

Turcot syndrome, Mesothelioma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Neuroendocrine Tumors, Microsatellite Instability

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡